

Claims

1. A pharmaceutical composition for the treatment of
tear and salivary fluid drying, which comprises (-)-(S)-
5 2,8-dimethyl-3-methylene-1-oxa-8-azaspiro[4.5]decane or a
pharmaceutically acceptable salt thereof as the active
ingredient.

2. The pharmaceutical composition for the treatment
10 of tear and salivary fluid drying described in claim 1,
wherein the active ingredient is L-tartarate monohydrate of
the compound described in claim 1.

3. The pharmaceutical composition described in claim
15 1, which has a selective tear and salivary fluid secretion
acceleration action.

4. The pharmaceutical composition described in claim
1 or 3, which has a glandular cell growth action.

20

5. The pharmaceutical composition described in claim
1 or 3, which has a sustained release preparation form.

6. The pharmaceutical composition described in claim
25 5, which comprises the compound described in claim 1, or a

pharmaceutically acceptable salt thereof, and a sustained release pharmaceutical carrier.

7. The pharmaceutical composition described in claim
5 2, whose applicable disease is rheumatism, autoimmune
diseases, medical diseases, atrophy of salivary gland and
lacrimal gland due to aging, allergic keratitis and
conjunctivitis, viral diseases, salivary gland and lacrimal
gland disorders due to radiation irradiation, aging,
10 psychological fatigue and dryness caused by a side effect
at the time of drug administration.